Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma
S Ferrero, D Grimaldi, E Genuardi… - Blood, The Journal …, 2022 - ashpublications.org
Minimal residual disease (MRD) analysis is a known predictive tool in mantle cell lymphoma
(MCL). We describe MRD results from the Fondazione Italiana Linfomi phase 3 MCL0208 …
(MCL). We describe MRD results from the Fondazione Italiana Linfomi phase 3 MCL0208 …
Ficoll‐hypaque separation vs whole blood lysis: comparison of efficiency and impact on minimal residual disease analysis
E Genuardi, D Barbero, I Dogliotti… - International Journal …, 2018 - Wiley Online Library
Introduction The high‐throughput era remarkably changed molecular laboratory practice.
Actually, the increasing number of processed samples requires to reduce the risk of operator …
Actually, the increasing number of processed samples requires to reduce the risk of operator …
[HTML][HTML] The combination of rituximab and bendamustine as first-line treatment is highly effective in the eradicating minimal residual disease in follicular lymphoma: an …
S Galimberti, E Ciabatti, G Ercolano, S Grassi… - Frontiers in …, 2017 - frontiersin.org
R-Bendamustine is an effective treatment for follicular lymphoma (FL). Previous large trials
demonstrated the prognostic role of the molecular minimal residual disease (MRD) during …
demonstrated the prognostic role of the molecular minimal residual disease (MRD) during …
Methods of glioma sample processing for molecular diagnosis for the glioma tissue bank project
Genome-wide sequencing in glioma samples provides comprehensive insights into
oncogenesis and malignant transformation. Several distinct biomarkers have been proven to …
oncogenesis and malignant transformation. Several distinct biomarkers have been proven to …
Resolving the diagnostic dilemma of T-cell clonal expansion after hematopoietic stem cell transplantation in T-cell lymphoma patients by TCR-gamma next generation …
PP Piccaluga, D Rapezzi, A Gazzola… - Bone Marrow …, 2019 - nature.com
Peripheral T-cell lymphomas (PTCLs) are rare tumors in Western countries, representing
about 10% of all non-Hodgkin's lymphomas (NHL)[1]. Despite their pathobiological [2] and …
about 10% of all non-Hodgkin's lymphomas (NHL)[1]. Despite their pathobiological [2] and …
[PDF][PDF] Journal of Clinical Case Reports, Medical Images and Health Sciences
F Aouidat, M Khan, X Li, F Tielens… - …, 2022 - jmedcasereportsimages.org
The development of biopolymers as building blocks, for the synthesis of Gd (II)
nanoparticles, as therapeutic, could play a key role in nanomedicine. Biopolymers are not …
nanoparticles, as therapeutic, could play a key role in nanomedicine. Biopolymers are not …
[HTML][HTML] Quality assessment for PCR-based minimal residual disease in Lymphoma: 10 Years of cross-laboratory standardization process within the fondazione …
B Mantoan, E Genuardi, M Ferrante, I Della Starza… - …, 2021 - journals.lww.com
Three decades ago, the first PCR-based approach for monoclonal detection in B-
lymphoproliferative disorders was published. 1 Nowadays, a real-time quantitative …
lymphoproliferative disorders was published. 1 Nowadays, a real-time quantitative …